{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:38:30Z","timestamp":1786541910315,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005147","name":"Applied Basic Research Key Project of Yunnan Province","doi-asserted-by":"publisher","award":["202401AY070001-025"],"award-info":[{"award-number":["202401AY070001-025"]}],"id":[{"id":"10.13039\/501100005147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360459"],"award-info":[{"award-number":["82360459"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55621-7","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:47:54Z","timestamp":1780393674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FAM111B may promote the progression of lung squamous cell carcinoma through PI3K signaling pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Yajuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruotian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoxiu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxiang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"55621_CR1","unstructured":"GLOBOCAN 2023. International Agency for Research on Cancer. http:\/\/gco.iarc.fr\/. Accessed 13 Mar 2025 (WHO, 2023)."},{"key":"55621_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-3-319-40389-2_2","volume":"170","author":"J Rodriguez-Canales","year":"2016","unstructured":"Rodriguez-Canales, J., Parra-Cuentas, E. & Wistuba, I. I. Diagnosis and molecular classification of lung cancer. Cancer Treat. Res. 170, 25\u201346. https:\/\/doi.org\/10.1007\/978-3-319-40389-2_2 (2016).","journal-title":"Cancer Treat. Res."},{"key":"55621_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345. https:\/\/doi.org\/10.3322\/caac.21871 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"55621_CR4","doi-asserted-by":"publisher","first-page":"e911","DOI":"10.1016\/j.cllc.2021.03.007","volume":"22","author":"CF Brainson","year":"2021","unstructured":"Brainson, C. F. et al. Description of a lung cancer hotspot: Disparities in lung cancer histology, incidence, and survival in Kentucky and Appalachian Kentucky. Clin. Lung Cancer. 22, e911\u2013e920. https:\/\/doi.org\/10.1016\/j.cllc.2021.03.007 (2021).","journal-title":"Clin. Lung Cancer"},{"key":"55621_CR5","doi-asserted-by":"publisher","first-page":"30998","DOI":"10.1038\/s41598-024-81965-z","volume":"14","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. Squamous cell carcinoma predicts worse prognosis in stage IA (\u2264\u20092\u00a0cm) non-small cell lung cancer patients following sublobectomy: A population-based study. Sci. Rep. 14, 30998. https:\/\/doi.org\/10.1038\/s41598-024-81965-z (2024).","journal-title":"Sci. Rep."},{"key":"55621_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cllc.2022.06.002","volume":"23","author":"ES Santos","year":"2022","unstructured":"Santos, E. S. & Rodriguez, E. Treatment considerations for patients with advanced squamous cell carcinoma of the lung. Clin. Lung Cancer. 23, 457\u2013466. https:\/\/doi.org\/10.1016\/j.cllc.2022.06.002 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"55621_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41392-022-01200-x","volume":"7","author":"Z Niu","year":"2022","unstructured":"Niu, Z., Jin, R., Zhang, Y. & Li, H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: Mechanisms and clinical trials. Signal. Transduct. Target. Ther. 7, 353. https:\/\/doi.org\/10.1038\/s41392-022-01200-x (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"55621_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.lungcan.2022.08.016","volume":"172","author":"A Addeo","year":"2022","unstructured":"Addeo, A. et al. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19\/18 phase II study. Lung Cancer. 172, 154\u2013159. https:\/\/doi.org\/10.1016\/j.lungcan.2022.08.016 (2022).","journal-title":"Lung Cancer"},{"key":"55621_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s11523-017-0513-6","volume":"12","author":"N Hashemi-Sadraei","year":"2017","unstructured":"Hashemi-Sadraei, N. & Hanna, N. Targeting FGFR in squamous cell carcinoma of the lung. Target. Oncol. 12, 741\u2013755. https:\/\/doi.org\/10.1007\/s11523-017-0513-6 (2017).","journal-title":"Target. Oncol."},{"key":"55621_CR10","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1002\/cam4.5311","volume":"12","author":"L Ji","year":"2023","unstructured":"Ji, L. et al. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells. Cancer Med. 12, 5688\u20135702. https:\/\/doi.org\/10.1002\/cam4.5311 (2023).","journal-title":"Cancer Med."},{"key":"55621_CR11","doi-asserted-by":"publisher","first-page":"111747","DOI":"10.1016\/j.intimp.2024.111747","volume":"130","author":"X Xue","year":"2024","unstructured":"Xue, X. et al. PI3K\u03b1 inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells. Int. Immunopharmacol. 130, 111747. https:\/\/doi.org\/10.1016\/j.intimp.2024.111747 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"55621_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2019.09.002","volume":"137","author":"B Besse","year":"2019","unstructured":"Besse, B. et al. A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. Lung Cancer. 137, 136\u2013143. https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.002 (2019).","journal-title":"Lung Cancer"},{"key":"55621_CR13","doi-asserted-by":"publisher","first-page":"5990","DOI":"10.1158\/1078-0432.Ccr-18-0717","volume":"24","author":"R Shi","year":"2018","unstructured":"Shi, R. et al. Targeting the CDK4\/6-Rb pathway enhances response to PI3K inhibition in PIK3CA-mutant lung squamous cell carcinoma. Clin. Cancer Res. 24, 5990\u20136000. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0717 (2018).","journal-title":"Clin. Cancer Res."},{"key":"55621_CR14","doi-asserted-by":"publisher","first-page":"1081166","DOI":"10.3389\/fmolb.2022.1081166","volume":"9","author":"AL Welter","year":"2022","unstructured":"Welter, A. L. & Machida, Y. J. Functions and evolution of FAM111 serine proteases. Front. Mol. Biosci. 9, 1081166. https:\/\/doi.org\/10.3389\/fmolb.2022.1081166 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"55621_CR15","doi-asserted-by":"publisher","first-page":"932167","DOI":"10.3389\/fonc.2022.932167","volume":"12","author":"A Arowolo","year":"2022","unstructured":"Arowolo, A., Malebana, M., Sunda, F. & Rhoda, C. Proposed cellular function of the human FAM111B protein and dysregulation in fibrosis and cancer. Front. Oncol. 12, 932167. https:\/\/doi.org\/10.3389\/fonc.2022.932167 (2022).","journal-title":"Front. Oncol."},{"key":"55621_CR16","doi-asserted-by":"publisher","unstructured":"Huang, N. et al. FAM111B acts as an oncogene in bladder cancer. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15215122 (2023).","DOI":"10.3390\/cancers15215122"},{"key":"55621_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2147\/ijgm.S409690","volume":"16","author":"H Wu","year":"2023","unstructured":"Wu, H. & Liang, C. Pan-cancer analysis of the tumorigenic effect and prognostic diagnostic value of FAM111B in human carcinomas. Int. J. Gen. Med. 16, 1845\u20131865. https:\/\/doi.org\/10.2147\/ijgm.S409690 (2023).","journal-title":"Int. J. Gen. Med."},{"key":"55621_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1177\/15353702231160326","volume":"248","author":"W Wang","year":"2023","unstructured":"Wang, W., Gu, Y., Ni, H., Quan, Q. & Guo, L. Silencing of FAM111B inhibits tumor growth and promotes apoptosis by decreasing AKT activity in ovarian cancer. Exp. Biol. Med. (Maywood). 248, 1043\u20131055. https:\/\/doi.org\/10.1177\/15353702231160326 (2023).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"55621_CR19","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1016\/j.clbc.2021.10.008","volume":"22","author":"W Li","year":"2022","unstructured":"Li, W., Hu, S., Han, Z. & Jiang, X. YY1-induced transcriptional activation of FAM111B contributes to the malignancy of breast cancer. Clin. Breast Cancer. 22, e417\u2013e425. https:\/\/doi.org\/10.1016\/j.clbc.2021.10.008 (2022).","journal-title":"Clin. Breast Cancer"},{"key":"55621_CR20","doi-asserted-by":"publisher","first-page":"107926","DOI":"10.1016\/j.compbiolchem.2023.107926","volume":"106","author":"S Gupta","year":"2023","unstructured":"Gupta, S., Silveira, D. A. & Hashimoto, R. F. A Boolean model of the oncogene role of FAM111B in lung adenocarcinoma. Comput. Biol. Chem. 106, 107926. https:\/\/doi.org\/10.1016\/j.compbiolchem.2023.107926 (2023).","journal-title":"Comput. Biol. Chem."},{"key":"55621_CR21","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele, W. & Stegner, H. E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8, 138\u2013140 (1987).","journal-title":"Pathologe"},{"key":"55621_CR22","first-page":"34","volume":"59","author":"M Kanehisa","year":"1996","unstructured":"Kanehisa, M. Toward pathway engineering: A new database of genetic and molecular pathways. Sci. Technol. Japan 59, 34\u201338 (1996).","journal-title":"Sci. Technol. Japan"},{"key":"55621_CR23","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"key":"55621_CR24","doi-asserted-by":"publisher","first-page":"12907","DOI":"10.18632\/aging.205210","volume":"15","author":"GQ Song","year":"2023","unstructured":"Song, G. Q. et al. The necroptosis signature and molecular mechanism of lung squamous cell carcinoma. Aging (Albany NY). 15, 12907\u201312926. https:\/\/doi.org\/10.18632\/aging.205210 (2023).","journal-title":"Aging (Albany NY)"},{"key":"55621_CR25","doi-asserted-by":"publisher","first-page":"107430","DOI":"10.1016\/j.compbiomed.2023.107430","volume":"165","author":"HK Joon","year":"2023","unstructured":"Joon, H. K., Thalor, A. & Gupta, D. Machine learning analysis of lung squamous cell carcinoma gene expression datasets reveals novel prognostic signatures. Comput. Biol. Med. 165, 107430. https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107430 (2023).","journal-title":"Comput. Biol. Med."},{"key":"55621_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s13205-023-03489-z","volume":"13","author":"R Guttapadu","year":"2023","unstructured":"Guttapadu, R. et al. Identification of novel biomarkers for lung squamous cell carcinoma. 3 Biotech. 13, 72 (2023).","journal-title":"3 Biotech."},{"key":"55621_CR27","doi-asserted-by":"publisher","first-page":"10650","DOI":"10.1111\/jcmm.17002","volume":"25","author":"AJ Massey","year":"2021","unstructured":"Massey, A. J., Benwell, K., Burbridge, M., Kotschy, A. & Walmsley, D. L. Targeting DYRK1A\/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma. J. Cell. Mol. Med. 25, 10650\u201310662. https:\/\/doi.org\/10.1111\/jcmm.17002 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"55621_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12985-022-01839-6","volume":"19","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Duck hepatitis A virus type 1 mediates cell cycle arrest in the S phase. Virol. J. 19, 111. https:\/\/doi.org\/10.1186\/s12985-022-01839-6 (2022).","journal-title":"Virol. J."},{"key":"55621_CR29","doi-asserted-by":"publisher","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","volume":"65","author":"EJ Hanan","year":"2022","unstructured":"Hanan, E. J. et al. Discovery of GDC-0077 (Inavolisib), a highly selective inhibitor and degrader of mutant PI3K\u03b1. J. Med. Chem. 65, 16589\u201316621. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01422 (2022).","journal-title":"J. Med. Chem."},{"key":"55621_CR30","doi-asserted-by":"publisher","first-page":"105303","DOI":"10.1016\/j.esmoop.2025.105303","volume":"10","author":"V Gambardella","year":"2025","unstructured":"Gambardella, V. et al. Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). ESMO Open 10, 105303. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105303 (2025).","journal-title":"ESMO Open"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55621-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55621-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55621-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:07:35Z","timestamp":1786540055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55621-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55621"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55621-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8974853\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments in the present study were conducted in accordance with the regulations for the administration of affairs concerning experimental animals and relevant institutional guidelines. The experiments were approved by the Ethical Committee of Kunming Medical University (Approval no. KMMU2020016 for animal experiments and KMMU2020MEC053 for human study).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research content involving human tissues and personal information in this study has been signed with the informed consent form of the patient, and the patient\u2019s consent for publication has been obtained.","order":3,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25082"}}